Navigation Links
The First Treatment Specifically Approved for Huntington's Disease Patients is Now Available in the United States
Date:11/24/2008

NEW YORK, Nov. 24 /PRNewswire/ -- Xenazine(R) (tetrabenazine) Tablets, the first and only U.S. Food and Drug Administration (FDA) approved drug for the treatment of chorea associated with Huntington's Disease (HD), is now available in the United States. Patients, caregivers, physicians and family members have been waiting for decades for a single treatment option. The Huntington's Disease Society of America is pleased that for the first time ever people with HD will have an approved option to consider to treat their chorea. Xenazine, which lessons the effects of chorea, will be distributed by Ovation Pharmaceuticals through a network of specialty pharmacies.

"The launch of Xenazine represents a significant milestone for the patients, families and caregivers affected by HD. After years of advocating for the approval of Xenazine, we are so pleased that it is now available here in the U.S. and that Ovation is committed to making this product accessible to as many individuals as possible who are living with this rare and devastating condition," said Barbara Boyle, National Executive Director/CEO, Huntington's Disease Society of America. Ovation has developed comprehensive patient support programs to ensure that as many qualified individuals as possible can receive Xenazine and to mitigate patients having problems accessing the drug due to financial constraints.

    To find out more about Xenazine and if it is the right treatment for you:

    -- Go see your physician
    -- Call 1-888-882-6013
    -- Visit Xenazineusa.com

Huntington's Disease is a devastating hereditary brain disorder with limited effective treatment options. HD slowly diminishes the affected individual's ability to walk, talk and reason. Eventually, the person with HD becomes totally dependent upon others for his or her care. Huntington's Disease profoundly affects the lives of entire families -- emotionally, socially and economically More than a quarter of a million Americans have HD or are "at risk" of inheriting the disease from an affected parent. HD affects as many people as Hemophilia, Cystic Fibrosis or ALS. HD affects males and females equally in all ethnicities. Each child of a person with HD has a 50 percent chance of inheriting the fatal gene. Everyone who carries the defective gene will develop the disease.

For some individuals, HD begins with chorea, a symptom present in an estimated 90 percent of people with HD. Chorea is a debilitating movement disorder characterized by excessive, involuntary and repetitive movements that are one of the most visible manifestations of Huntington Disease. Chorea interferes with individuals' ability to perform activities of daily living, including dressing, bathing and caring for themselves.

About Huntington's Disease Society of America

Huntington's Disease Society of America (HDSA) is a national non-profit organization dedicated to finding a cure for Huntington's Disease (HD) while providing support and services for those living with HD and their families. HDSA promotes and supports both clinical and basic HD research, aids families in coping with the multi-faceted problems presented by HD and educates the families, the public and health care professionals about Huntington's Disease. For more information call (800)-345-HDSA, visit http://www.hdsa.org or e-mail hdsainfo@hdsa.org.


'/>"/>
SOURCE Huntington's Disease Society of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
2. ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States
3. Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry
4. Life-Saving Airman, Leukemia Patient Meet for First Time
5. First Lady Laura Bushs Partnership for Breast Cancer Awareness and Research Extends to Panama
6. First Lady Laura Bushs Partnership for Breast Cancer Awareness and Research extends to Panama
7. Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income
8. NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan
9. China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008
10. Healthplace America Delivers the First and Only Surgery Benefit Management Solution Through the Healthplace Benefit(TM)
11. Three-Quarters of Americans and Industry Leaders Want Health Care Reform in President-elect Obamas First Term
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... 2017 , ... The American Board of Quality Assurance and Utilization Review Physicians ... to Health Care Quality and Management and Patient Safety. , It is with appreciation ... but also to the Health Care Quality and Patient Safety movements. Diplomates and Members ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, ... How will the new EU MDR language change the way manufacturers approach ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Beyond and ... “Beyond and Back” is the creation of published author Bonetta Rose, a wife, mother ... our lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology: